company background image
EXEL

ExelixisNasdaqGS:EXEL Stock Report

Market Cap

US$5.4b

7D

-1.8%

1Y

-11.7%

Updated

30 Nov, 2021

Data

Company Financials +
EXEL fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance2/6
Financial Health6/6
Dividends0/6

EXEL Stock Overview

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States.

Exelixis Competitors

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$68.4b

Seagen

NasdaqGS:SGEN

US$30.2b

Incyte

NasdaqGS:INCY

US$15.5b

Blueprint Medicines

NasdaqGS:BPMC

US$5.8b

Price History & Performance

Summary of all time highs, changes and price drops for Exelixis
Historical stock prices
Current Share PriceUS$16.91
52 Week HighUS$25.77
52 Week LowUS$16.19
Beta0.93
1 Month Change-21.39%
3 Month Change-11.79%
1 Year Change-11.74%
3 Year Change-21.35%
5 Year Change-5.16%
Change since IPO11.34%

Recent News & Updates

Nov 28

Exelixis: Recent Q3 Selloff Offers A Compelling Opportunity

Since the last earnings report, shares of Exelixis declined over 20% because of a slight adjustment of the FJ outlook. Total revenue is still likely to grow 35% in FJ 2021 at the midpoint of the updated guidance. The company continues to expand the Cabometxy label with further indications, ensuring stable growth in the coming years. Valuation does not look very expensive with a forward EV/Sales of 2.6 and a forward P/E of 23.2 given the prospects.

Shareholder Returns

EXELUS BiotechsUS Market
7D-1.8%2.0%-0.9%
1Y-11.7%4.9%23.3%

Return vs Industry: EXEL underperformed the US Biotechs industry which returned 5.3% over the past year.

Return vs Market: EXEL underperformed the US Market which returned 21.3% over the past year.

Price Volatility

Is EXEL's price volatile compared to industry and market?
EXEL volatility
EXEL Average Weekly Movement5.3%
Biotechs Industry Average Movement8.6%
Market Average Movement6.0%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market2.3%

Stable Share Price: EXEL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: EXEL's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1994773Mike Morrisseyhttps://www.exelixis.com

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company’s products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.

Exelixis Fundamentals Summary

How do Exelixis's earnings and revenue compare to its market cap?
EXEL fundamental statistics
Market CapUS$5.35b
Earnings (TTM)US$164.29m
Revenue (TTM)US$1.25b

32.6x

P/E Ratio

4.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EXEL income statement (TTM)
RevenueUS$1.25b
Cost of RevenueUS$46.29m
Gross ProfitUS$1.21b
ExpensesUS$1.04b
EarningsUS$164.29m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.52
Gross Margin96.31%
Net Profit Margin13.10%
Debt/Equity Ratio0%

How did EXEL perform over the long term?

See historical performance and comparison

Valuation

Is Exelixis undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: EXEL ($16.91) is trading below our estimate of fair value ($68.28)

Significantly Below Fair Value: EXEL is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: EXEL is poor value based on its PE Ratio (32.6x) compared to the US Biotechs industry average (25x).

PE vs Market: EXEL is poor value based on its PE Ratio (32.6x) compared to the US market (17.1x).


Price to Earnings Growth Ratio

PEG Ratio: EXEL is good value based on its PEG Ratio (0.8x)


Price to Book Ratio

PB vs Industry: EXEL is good value based on its PB Ratio (2.5x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Exelixis forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

39.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EXEL's forecast earnings growth (39.3% per year) is above the savings rate (2%).

Earnings vs Market: EXEL's earnings (39.3% per year) are forecast to grow faster than the US market (14.3% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: EXEL's revenue (15.4% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: EXEL's revenue (15.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: EXEL's Return on Equity is forecast to be low in 3 years time (16.8%).


Past Performance

How has Exelixis performed over the past 5 years?

13.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EXEL has high quality earnings.

Growing Profit Margin: EXEL's current net profit margins (13.1%) are lower than last year (15.9%).


Past Earnings Growth Analysis

Earnings Trend: EXEL has become profitable over the past 5 years, growing earnings by 13% per year.

Accelerating Growth: EXEL's earnings growth over the past year (8%) is below its 5-year average (13% per year).

Earnings vs Industry: EXEL earnings growth over the past year (8%) underperformed the Biotechs industry 11%.


Return on Equity

High ROE: EXEL's Return on Equity (7.8%) is considered low.


Financial Health

How is Exelixis's financial position?


Financial Position Analysis

Short Term Liabilities: EXEL's short term assets ($1.7B) exceed its short term liabilities ($269.5M).

Long Term Liabilities: EXEL's short term assets ($1.7B) exceed its long term liabilities ($65.8M).


Debt to Equity History and Analysis

Debt Level: EXEL is debt free.

Reducing Debt: EXEL has no debt compared to 5 years ago when its debt to equity ratio was 584.6%.

Debt Coverage: EXEL has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: EXEL has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Exelixis's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EXEL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EXEL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EXEL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EXEL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EXEL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.3yrs

Average management tenure


CEO

Mike Morrissey (60 yo)

11.33yrs

Tenure

US$2,349,812

Compensation

Dr. Michael M. Morrissey, Ph D., also known as Mike, has been the Chief Executive Officer and President of Exelixis, Inc. since July 2010. Dr. Morrissey served as the President of Research and Development...


CEO Compensation Analysis

Compensation vs Market: Mike's total compensation ($USD2.35M) is below average for companies of similar size in the US market ($USD6.23M).

Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: EXEL's management team is seasoned and experienced (6.3 years average tenure).


Board Members

Experienced Board: EXEL's board of directors are seasoned and experienced ( 17.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Exelixis, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Exelixis, Inc.
  • Ticker: EXEL
  • Exchange: NasdaqGS
  • Founded: 1994
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$5.350b
  • Shares outstanding: 316.40m
  • Website: https://www.exelixis.com

Number of Employees


Location

  • Exelixis, Inc.
  • 1851 Harbor Bay Parkway
  • Alameda
  • California
  • 94502
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/30 00:09
End of Day Share Price2021/11/29 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.